NASDAQ:SXTC China SXT Pharmaceuticals Q2 2026 Earnings Results & Report $0.34 -2.49 (-87.99%) Closing price 04:00 PM EasternExtended Trading$0.39 +0.05 (+14.41%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. China SXT Pharmaceuticals reported Q2 2026 earnings on December 31, 2025. The company reported EPS of -$360.00, while revenue was $0.31 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateDecember 31, 2025TimeAfter Market Closes China SXT Pharmaceuticals EPS ResultsActual EPS-$360.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AChina SXT Pharmaceuticals Revenue ResultsActual Revenue$0.31 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile China SXT Pharmaceuticals Q2 2026 Earnings FAQ Did China SXT Pharmaceuticals beat earnings estimates for Q2 2026? China SXT Pharmaceuticals (NASDAQ:SXTC) reported earnings of -$360.00 per share for Q2 2026. The report was announced on Wednesday, December 31, 2025. What was China SXT Pharmaceuticals' revenue for Q2 2026? China SXT Pharmaceuticals reported revenue of $0.31 million for Q2 2026. China SXT Pharmaceuticals Earnings HeadlinesChina SXT Secures $12 Million Financing Through Registered Direct Offering; Stock Down2 hours ago | rttnews.comChina SXT Pharmaceuticals announces $12 million registered direct offering with significant dilution potentialOctober 8 at 1:15 PM | msn.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 8 at 1:00 AM | The Oxford Club (Ad)China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct OfferingOctober 8 at 9:22 AM | prnewswire.comChina SXT Pharmaceuticals Terminates $3 Million Offshore Share and Warrant OfferingOctober 8 at 8:10 AM | tipranks.comChina SXT Pharmaceuticals, Inc. Announces Share ConsolidationAugust 5, 2026 | globenewswire.comSee More China SXT Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like China SXT Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on China SXT Pharmaceuticals and other key companies, straight to your email. Email Address About China SXT PharmaceuticalsChina SXT Pharmaceuticals (NASDAQ:SXTC) is a China-based pharmaceutical company focused on the development, manufacture and sale of traditional Chinese medicine products. The company’s offerings are designed for use in traditional medicine and health care applications and are marketed primarily in China. Its product portfolio includes traditional Chinese medicine decoction pieces, finished traditional Chinese medicines and health care products. These products are sold through distribution and retail channels serving pharmacies, medical institutions and other health care-related customers. The company has also described its products as including prescription medicines, over-the-counter medicines and dietary or health supplements. China SXT Pharmaceuticals is based in Taizhou, Jiangsu Province, China, and has historically operated manufacturing facilities in the region. The company completed its initial public offering on the Nasdaq under the symbol SXTC in 2019. Its business remains centered on traditional Chinese medicine production and distribution within the Chinese market.View China SXT Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
